(Reuters) – AstraZeneca is creating a separate division for vaccines and antibody therapies to be led by senior executive Iskra Reić, the drugmaker said on Tuesday, as it builds focus on its COVID-19 shot and development of coronavirus treatments.
Reuters in July reported that the Anglo-Swedish company was exploring options for its vaccine business and expected to have greater clarity on the matter by the end of 2021.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Anil D’Silva)
